Don’t miss the Hot Topics Session – ESICM Lives 2019! Dr Jean-Baptiste LASCARROU (Nantes, FRANCE) will report study results live in BERLIN during the next ESICM congress (Lives 2019).

Hyperion was an open-label randomized controlled trial comparing moderate therapeutic hypothermia (33°C during the first 24 hours) to targeted normothermia (37°C) in comatose patients admitted to intensive care units after resuscitation from cardiac arrest with nonshockable rhythm. The primary outcome was survival with a favorable neurological outcome, assessed on post-randomization day 90 using the CPC scale.  A favorable neurological outcome was defined as CPC 1 or 2. Between January 2014 and January 2018, 584 patients were included and results will be release at ESICM 2019 during the hot topic session.